Rigel Pharmaceuticals, Inc.

Equities

RIGL

US7665597024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
8.22 ^USD	-13.75%		-13.47%	-43.31%

06-25	Rigel Pharmaceuticals to Implement 1-for-10 Reverse Stock Split	MT
06-25	Sector Update: Health Care Stocks Advance Pre-Bell Tuesday	MT

Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

March 05, 2024 at 09:01 pm

Rigel Pharmaceuticals, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 35.79 million compared to USD 51.28 million a year ago. Net income was USD 0.737 million compared to USD 1.4 million a year ago.
For the full year, revenue was USD 116.88 million compared to USD 120.24 million a year ago. Net loss was USD 25.09 million compared to USD 58.57 million a year ago. Basic loss per share from continuing operations was USD 1.4 compared to USD 3.4 a year ago.

Latest news about Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals to Implement 1-for-10 Reverse Stock Split	06-25	MT
Sector Update: Health Care Stocks Advance Pre-Bell Tuesday	06-25	MT
Rigel Pharmaceuticals Completes Transfer of Gavreto New Drug Application	06-24	MT
Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application	06-24	CI
Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress	06-14	CI
Transcript : Rigel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M	05-07	MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Rigel Pharmaceuticals, Inc. Enters into Amendment No. 4 to that Certain Credit and Security Agreement	04-12	CI
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer	03-12	CI
Citigroup Adjusts Rigel Pharmaceuticals' Price Target to $4 From $3, Maintains Buy Rating	03-07	MT
Transcript : Rigel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 05, 2024	03-05
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, vs. Street Est of $33.4M	03-05	MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-05	CI
B. Riley Lifts Rigel Pharmaceuticals' PT to $1.75 From $1.25 After Announced Purchase of US Rights to Gavreto From Blueprint Medicines; Keeps Neutral Rating	02-26	MT
Rigel Pharmaceuticals Seeks Acquisitions	01-11	CI
Transcript : Rigel Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 12:00 PM	01-11
Rigel Pharmaceuticals Enters Collaboration to Study Possible Treatment for Brain Tumors; Shares Rise	01-04	MT
Rigel Pharmaceuticals, Inc. Announces Collaboration with Connect to Conduct a Phase 2 Trial of Olutasidenib in Glioma	01-04	CI
Rigel Pharmaceuticals, MD Anderson Partner for Research on New Rezlidhia Indications	12-08	MT
Rigel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center Announce Strategic Alliance to Advance REZLIDHIA®? (Olutasidenib) in AML and Other Cancers	12-08	CI
B. Riley Trims Rigel Pharmaceuticals' PT to $1.25 From $1.75, Lowers Peak Sales Estimate for Rezlidhia; Maintains Neutral Rating	11-09	MT
Transcript : Rigel Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 07, 2023	11-07
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q3 Revenue $28.1M, vs. Street Est of $27.2M	11-07	MT

Chart Rigel Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Sector

Biotechnology & Medical Research

Calendar

29/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Rigel Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.22 USD

Average target price

65.33 USD

Spread / Average Target

+694.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RIGEL PHARMACEUTICALS, INC.	-43.31%	144M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs